Stavir belongs to synthetic thymidine nucleoside analogue andtype of antiretroviral agents. Mostly the drug Stavir is effective against the human immunodeficiency virus type 1 (HIV-1) and AIDS and it’s not applicable for first line treatment Stavir also a type of dideoxynucleoside analog which prevents the reverse transcriptase and has in vitro activity against HIV. Stavir is not a cure for HIV or AIDS and it is a prescription drug which is used under guidance of physician
Stavir capsules co administration with other antiretroviral drugs which are indicatedfor the treatment of human immunodeficiency virus (HIV)-1 infection.
Stavir is may alsonecessary for inhibition after a needlestick injury or other potential exposure.
Mechanism of action
Stavudine belongs to a nucleoside analogue of thymidine, is adding of phosphate group by cellular kinases to the active metabolite stavudine triphosphate.
Stavudine triphosphate prohibits the activity of HIV-1 reverse transcriptase (RT) by fighting with the natural substrate thymidine triphosphate (Ki=0.0083 to 0.032 μM) and by causing DNA chain termination following its incorporation into viral DNA.
Stavudine triphosphate prohibits cellular DNA polymerases β and γ and markedly reduces the synthesis of mitochondrial DNA.
Fastly absorbed with highserum concentrations occurring within1 hour after dosing.
Human plasma protein bounding is negligible
The active substrate for HIV- reverse transcriptase is phosphorylated intracellularly to Stavudine triphosphate.
The total radioactivity was eliminated in urine 95% and feces 3% respectively. Stavudine administrating to healthy subjects following 80mg dose.
The prescribed dose of the adult to treat of HIV infection The dosage of Stavir is mainlybased on body weight as follows: Administer 30mg every 12 hours for the patients weighing < 60kg. Administered 40mg every 12 hours for the patients weighing at least 60kg
The prescribed dose for pediatrics For new borns from birth to 13 days old given 0.5mg/kg given 12 hours For pediatric patients at least 14 days old administered 1mg/kg given every 12 hours Use same adult dose for pediatric patients weighing at least 30kg
The recommended daily dosage exposes no acute antitoxin. The chronic dosage complexityincludes peripheral neuropathy and hepatic toxicity. Stavudine can be removed by hemodialysis
Neurologic symptoms occur when motor weakness has been resulted rarely in patients getting combination with antiretroviral treatment including Stavudine and patients should be monitored for the growth of peripheral neuropathy.
Hepatic toxicity will occur in HIV patients with significant underlying liver disease, the safety and efficacy of stavudine have not been established. If combination with antiretroviral therapy, some serious problem arises and potentially fatal hepatic adverse events and should be checked according to standard practice.
Lactic acidosis causes inSevere hepatomegaly with steatosis and lactic acidosis with the use in combination or nucleoside analogues involves stavudine and other antiretrovirals.
Fat redistribution will cause by Redistribution/aggregation of body fat involving central obesity, dorsocervical fat augmentation (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed in patients getting antiretroviral therapy.